GlassScriptPhysician profile
Qingting Lin
NPI 1093543332
$1,858.91
in general payments reported to CMS, 2019-2025
19 companies · $912 in 2025
The $912 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $947 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.78 | 2024-2025 | |
| Gilead Sciences, INC. | $184.06 | 2024-2025 | Vemlidy, Livdelzi |
| Axsome Therapeutics, INC. | $121.84 | 2024 | Sunosi |
| Intercept Pharmaceuticals, INC. | $101.77 | 2024-2025 | |
| Madrigal Pharmaceuticals | $93.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $87.02 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $84.28 | 2025 | Iqirvo |
| Celltrion USA INC. | $82.25 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $81.93 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.26 | 2025 | Xifaxan |
| Janssen Biotech, INC. | $77.22 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $54.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $51.92 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $47.18 | 2024 | Entyvio |
| Medtronic, INC. | $44.72 | 2025 | Pillcam |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.68 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $36.30 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $35.46 | 2024-2025 | Ibsrela |
| Digestive Care, INC. | $21.35 | 2024 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qingting Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.